Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

DNAmod: the DNA modification database.

Sood AJ, Viner C, Hoffman MM.

J Cheminform. 2019 Apr 23;11(1):30. doi: 10.1186/s13321-019-0349-4.

2.

Perspectives on fertility preservation and parenthood among transgender youth and their parents.

Chiniara LN, Viner C, Palmert M, Bonifacio H.

Arch Dis Child. 2019 Aug;104(8):739-744. doi: 10.1136/archdischild-2018-316080. Epub 2019 Mar 20.

PMID:
30894340
3.

Can the Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Program Be Provided Online? Voices from the Youth.

Chadi N, Weisbaum E, Malboeuf-Hurtubise C, Ahola Kohut S, Viner C, Kaufman M, Locke J, Vo DX.

Children (Basel). 2018 Aug 28;5(9). pii: E115. doi: 10.3390/children5090115.

4.

In-Person Versus eHealth Mindfulness-Based Intervention for Adolescents With Chronic Illness: Protocol for a Randomized Controlled Trial.

Chadi N, Kaufman M, Weisbaum E, Malboeuf-Hurtubise C, Kohut SA, Viner C, Locke J, Vo DX.

JMIR Res Protoc. 2017 Nov 27;6(11):e241. doi: 10.2196/resprot.7700.

5.

Do trials reduce uncertainty? Assessing impact through cumulative meta-analysis of neonatal RCTs.

Hay SC, Kirpalani H, Viner C, Soll R, Dukhovny D, Mao WY, Profit J, DeMauro SB, Zupancic JAF.

J Perinatol. 2017 Nov;37(11):1215-1219. doi: 10.1038/jp.2017.126. Epub 2017 Sep 7.

PMID:
28880258
6.

A Robust and Reliable Test to Measure Stereopsis in the Clinic.

Hess RF, Ding R, Clavagnier S, Liu C, Guo C, Viner C, Barrett BT, Radia K, Zhou J.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):798-804. doi: 10.1167/iovs.15-18690.

PMID:
26934135
7.

Determining the epigenome using DNA alone.

Viner C, Hoffman MM.

Nat Methods. 2015 Mar;12(3):191-2. doi: 10.1038/nmeth.3291. No abstract available.

PMID:
25719827
8.

Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer.

Dorman SN, Viner C, Rogan PK.

Sci Rep. 2014 Nov 14;4:7063. doi: 10.1038/srep07063.

9.

Validation of predicted mRNA splicing mutations using high-throughput transcriptome data.

Viner C, Dorman SN, Shirley BC, Rogan PK.

Version 2. F1000Res. 2014 Jan 13 [revised 2014 Jan 1];3:8. doi: 10.12688/f1000research.3-8.v2. eCollection 2014.

10.

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.

Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J, Gore M.

Br J Haematol. 1998 Jul;102(2):495-502.

PMID:
9695964
11.

Establishing ambulatory chemotherapy at home.

Dougherty L, Viner C, Young J.

Prof Nurse. 1998 Mar;13(6):356-8.

PMID:
9534556
12.

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.

Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D, Treleaven J.

Bone Marrow Transplant. 1997 Sep;20(6):435-43.

13.

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.

Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M.

Br J Haematol. 1997 Apr;97(1):153-60.

PMID:
9136958
14.

Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.

Powles R, Raje N, Horton C, Mehta J, Singhal S, Hickish T, Viner C, Milan S, Treleaven J, Cunningham D.

Leuk Lymphoma. 1996 May;21(5-6):421-7.

PMID:
9172806
15.

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.

O'Brien ME, Milan S, Cunningham D, Jones AL, Nicolson M, Selby P, Hickish T, Hill M, Gore ME, Viner C.

Br J Cancer. 1996 May;73(10):1272-7.

16.

Kinetics of paraprotein clearance after autografting for multiple myeloma.

Singhal S, Powles R, Milan S, Raje N, Viner C, Treleaven J, Raymond J, Cunningham D, Mehta J.

Bone Marrow Transplant. 1995 Oct;16(4):537-40.

PMID:
8528169
17.

Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.

Powles R, Raje N, Cunningham D, Malpas J, Milan S, Horton C, Mehta J, Singhal S, Viner C, Treleaven J.

Stem Cells. 1995 Aug;13 Suppl 2:114-7.

PMID:
8520498
18.

High-dose melphalan for multiple myeloma: long-term follow-up data.

Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ, et al.

J Clin Oncol. 1994 Apr;12(4):764-8.

PMID:
8151320
19.

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.

Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleavan J, Viner C, Malpas J, et al.

J Clin Oncol. 1994 Apr;12(4):759-63.

PMID:
8151319
20.

Repeat administration of high dose melphalan in relapsed myeloma.

Mansi JL, Cunningham D, Viner C, Ellis E, Meldrum M, Milan S, Gore M.

Br J Cancer. 1993 Nov;68(5):983-7.

21.

Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies.

Patel PM, Selby PJ, Graham MA, Viner C, Newell DR, McElwain TJ.

Hematol Oncol. 1993 Mar-Apr;11(2):89-96.

PMID:
8406379
23.

High-dose busulfan in patients with myeloma.

Mansi J, da Costa F, Viner C, Judson I, Gore M, Cunningham D.

J Clin Oncol. 1992 Oct;10(10):1569-73.

PMID:
1403036
24.

Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.

Mansi J, Ellis E, Viner C, Mundy J, Smith T, Millar J, Milan S, Gore M, Cunningham D.

Cancer Chemother Pharmacol. 1992;30(2):149-51.

PMID:
1600595
25.

A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma.

Jones AL, O'Brien ME, Lorentzos A, Viner C, Hanrahan A, Moore J, Millar JL, Gore ME.

Cancer Chemother Pharmacol. 1992;30(1):73-6.

PMID:
1586984
26.

High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.

Harding M, Selby P, Gore M, Perren T, Treleavan J, Mansi J, Zulian G, Milan S, Meldrum M, Viner C, et al.

Eur J Cancer. 1992;28A(8-9):1396-400.

PMID:
1515256
27.

Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.

Bell JB, Millar BC, Montes-Borinaga A, Joffe JK, Cunningham D, Mansi J, Treleaven J, Viner C, McElwain TJ.

Hematol Oncol. 1990 Nov-Dec;8(6):347-53.

PMID:
2286358
28.

Tumour necrosis factor, cholestatic jaundice, and chronic liver disease.

Jones A, Selby PJ, Viner C, Hobbs S, Gore ME, McElwain TJ.

Gut. 1990 Aug;31(8):938-9. No abstract available.

29.
30.

Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor.

Hardy J, Jones A, Gore ME, Viner C, Selby P, Wiltshaw E.

Eur J Cancer. 1990;26(6):771. No abstract available.

PMID:
2144175
31.

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

Viner CV, Selby PJ, Zulian GB, Gore ME, Butcher ME, Wootton CM, McElwain TJ.

Cancer Chemother Pharmacol. 1990;25(6):449-53.

PMID:
2138064
32.

VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.

McElwain TJ, Gore ME, Meldrum M, Viner C, Judson IR, Malpas JS.

Bone Marrow Transplant. 1989 Dec;4 Suppl 4:109-12.

PMID:
2697419
33.

Intensive treatment of multiple myeloma and criteria for complete remission.

Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B, Bell J, Maitland JA, Milan S, Judson IR, et al.

Lancet. 1989 Oct 14;2(8668):879-82.

PMID:
2571812
34.

High-dose chemotherapy and autologous bone marrow transplantation for myeloma.

McElwain TJ, Selby PJ, Gore ME, Viner C, Meldrum M, Millar BC, Malpas JS.

Eur J Haematol Suppl. 1989;51:152-6. Review.

PMID:
2697587
35.

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.

Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Maitland J, McElwain TJ.

Br J Cancer. 1988 Oct;58(4):469-73.

36.

The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies.

Selby P, Zulian G, Forgeson G, Nandi A, Milan S, Meldrum M, Viner C, Osborne R, Malpas JS, McElwain TJ.

Hematol Oncol. 1988 Apr-Jun;6(2):173-9. No abstract available.

PMID:
3292375
37.

Endogenous tumour necrosis factor in cancer patients.

Selby PJ, Hobbs S, Viner C, Jackson E, Smith IE, McElwain TJ.

Lancet. 1988 Feb 27;1(8583):483. No abstract available.

PMID:
2893913
38.

Tumour necrosis factor in man: clinical and biological observations.

Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, et al.

Br J Cancer. 1987 Dec;56(6):803-8.

39.

Pressure sores. Floating on a bed of beads.

Viner C.

Nurs Times. 1986 Feb 19-25;82(8):62-6. No abstract available.

PMID:
3634380

Supplemental Content

Support Center